Ionis' 4Q Spinraza Growth and Progressing Late-Stage Pipeline Offset by Increased Operating Costs
After Ionis’ fourth-quarter results, we are reiterating our $47 per share fair value estimate. Faster-than-expected uptake of Spinraza in patients with spinal muscular atrophy drove the company’s outperformance in the quarter. Looking ahead to 2018, we anticipate that our increased Spinraza forecasts will be offset by higher operating costs as the company and its majority-owned subsidiary Akcea prepare for two potential drug launches and support a growing pipeline. We model full-year operating e...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.